menu
    • menu
    [{"orgOrder":0,"company":"Exeltis","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Exeltis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Lupin Ltd"},{"orgOrder":0,"company":"Exeltis","sponsor":"Afaxys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Levonorgestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Exeltis \/ Afaxys Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Afaxys Pharma"},{"orgOrder":0,"company":"Exeltis","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fenticonazole Nitrate","moa":"sterol","graph1":"Undisclosed","graph2":"Phase I","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exeltis \/ Monitor CRO","highestDevelopmentStatusID":"6","companyTruncated":"Exeltis \/ Monitor CRO"}]

    Find Clinical Drug Pipeline Developments & Deals by Exeltis

    Menu

    Exeltis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Afaxys Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Afaxys and Exeltis Renew Partnership to Expand Access to Twirla Transdermal System

                            Details : The partnership aims to support access to Twirla (levonorgestrel and ethinyl estradiol), a low-dose, non-daily contraceptive transdermal system, in the public health market.

                            Product Name : Twirla

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            June 30, 2025

                            Lead Product(s) : Levonorgestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Afaxys Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenticonazole Nitrate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

                            Details : Fenticonazole nitrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2022

                            Lead Product(s) : Fenticonazole Nitrate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer’s Disease Treatmen...

                            Details : Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

                            Product Name : Rivalif

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secnidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) Expanding Access for Adult Women Suf...

                            Details : This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.

                            Product Name : Solosec

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : Secnidazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rizatriptan Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : IntelGenx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Intelgenx and Exeltis Healthcare S.L. Expand Rizaport® Commercialization Agreement to Include the European Un...

                            Details : Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

                            Product Name : Rizaport

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 27, 2020

                            Lead Product(s) : Rizatriptan Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : IntelGenx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Exeltis

                            Spain arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mexiletine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla®

                            Details : Under the agreements, Exeltis Healthcare will commercialize NaMuscla® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMus...

                            Product Name : NaMuscla

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 03, 2020

                            Lead Product(s) : Mexiletine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth